Finally, it was very recently demonstrated that drugs exhibiting a dual-action, i.e., Nrf2 activation and NF-kB inhibition, display neuroprotective properties in models of AD [158], PD [183,184], and MS [185], thus strengthening the idea that targeting multiple pathways in the astrocytes could correct the aberrant activities of these cells and, consequently, halt neurodegeneration. This evidence concerns the gene NFE2L2 and Parkinson disease.